trending Market Intelligence /marketintelligence/en/news-insights/trending/FLeH0-w8o2IVjLjEvBGm9Q2 content esgSubNav
In This List

Acceleron prices common stock offering to raise $230M

Blog

Insight Weekly: Private equity slows; SPAC underwriters retreat; carbon capture boost

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms


Acceleron prices common stock offering to raise $230M

Acceleron Pharma Inc. priced an underwritten public offering of its common shares at $43 apiece.

The Cambridge, Mass.-based biopharmaceutical company will sell 5,348,838 common shares to raise $230 million in gross proceeds. It has also granted the underwriters an option to buy up to an additional 802,325 shares.

Acceleron, which develops therapeutics to treat serious and rare diseases, expects to receive about $215.8 million in net proceeds, which will fund the development of its drug candidates and future development programs. The funds will also be used for general and administrative expenses, as well as capital expenditures, working capital and other general corporate purposes.

The offering is expected to close Jan. 18.

Citigroup, J.P. Morgan and SVB Leerink are acting as joint book-running managers for the offering, with UBS Investment Bank as lead manager.